<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147882">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767987</url>
  </required_header>
  <id_info>
    <org_study_id>ISR IN-US-259-0139</org_study_id>
    <nct_id>NCT01767987</nct_id>
  </id_info>
  <brief_title>Ranolazine Cardioprotection in PCI</brief_title>
  <official_title>Ranolazine Cardioprotection in PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvey Hahn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kettering Health Network</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker
      release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ranolazine has been demonstrated to decrease angina, ischemia on perfusion imaging, improve
      diastolic function, and cardiac metabolism. Furthermore it has been associated with reduced
      cardiac arrhythmias, including non-sustained ventricular tachycardia and atrial
      fibrillation. It has not been studied as an acute cardioprotective agent in percutaneous
      coronary intervention (PCI).

      We hypothesize that upfront administration of Ranolazine could decrease the myocardial
      injury associated with PCI due to all the factors listed above (i.e. precondition the
      myocardium). We plan to screen all patients scheduled for an elective coronary angiogram.
      Those who meet criteria and consent will be randomized to either receive Ranolazine or
      placebo twice a day for 3 days leading up to the PCI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Troponin</measure>
    <time_frame>8-10 hrs post PCI</time_frame>
    <safety_issue>No</safety_issue>
    <description>Troponin labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CK-MB</measure>
    <time_frame>8-10 hrs post PCI</time_frame>
    <safety_issue>No</safety_issue>
    <description>CK-MB labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TIMI flow rates</measure>
    <time_frame>During the PCI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of atrial fibrillation, ventricular tachycardia, or ventricular fibrillation in coronary cath lab</measure>
    <time_frame>During the PCI</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-sustained ventricular tachycardia or atrial fibrillation post PCI</measure>
    <time_frame>Following completion of PCI through hospital discharge</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end diastolic pressure (LVEDP)</measure>
    <time_frame>During the PCI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful PCI, death, myocardial infarction (biomarker greater than 2x normal), CHF, cardiac arrest</measure>
    <time_frame>At discharge or within 1 days, whichever comes first</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, MI, Revascularization, CHF</measure>
    <time_frame>1-4 weeks post PCI</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral treatment Intervention: Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Patients undergoing Coronary Angiography with possible PCI

          -  Able and willing to give consent

          -  Able to read and write English

        Exclusion Criteria:

          -  Current EKG or Biomarker of Acute Myocardial Infarction (MI) or Acute Coronary
             Syndromes (ACS)

          -  History of Allergy to Ranolazine

          -  Pregnant or Nursing

          -  Currently taking Ranolazine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harvey S Hahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kettering Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harvey S Hahn, MD</last_name>
    <phone>937-312-9890</phone>
    <email>harvey.hahn@khnetwork.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brandi L Palmer, MS</last_name>
    <phone>937-395-8227</phone>
    <email>brandi.palmer@khnetwork.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Harvey Hahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 2, 2013</lastchanged_date>
  <firstreceived_date>November 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kettering Health Network</investigator_affiliation>
    <investigator_full_name>Harvey Hahn</investigator_full_name>
    <investigator_title>Director, Cardiovascular Fellowship Training Program and Director,  Cardiac Noninvasive Laboratory</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>ACS</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>PCI</keyword>
  <keyword>Ranolazine</keyword>
  <keyword>Coronary Angiogram</keyword>
  <keyword>Cardioprotectant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
